MapLight Therapeutics

ML-007 Clin1 dyskinesias. Clin1 schizophrenia; ML-016 RD/Clin0 depression; ML-009 RD/Clin0 hyperactivity/impulsivity; ML-105 RD depression

MapLight Therapeutics is developing novel therapeutics for patients with disorders of the central nervous system. Given the complexity of the brain, diseases with highly specific symptoms should be treated with the same therapeutics. MapLight is using the combination of transcriptomics, optogenetics and STARmap to develop a strong pipeline of safe, effective therapeutics. Optogenetics is used to identify key cell types, transcriptomics is to find targets and STARmap is used to visualize neural circuits. MapLight has already brought two novel therapeutics to the clinic, with more on the horizon.